List of Excipients in Branded Drug ESTRADIOL GEL

Generic Drugs Containing ESTRADIOL GEL

Company	Ingredient	NDC	Excipient
Encube Ethicals Inc	estradiol	21922-086	ALCOHOL
Encube Ethicals Inc	estradiol	21922-086	CARBOMER HOMOPOLYMER TYPE B
Encube Ethicals Inc	estradiol	21922-086	PROPYLENE GLYCOL
Encube Ethicals Inc	estradiol	21922-086	TROLAMINE

What are the Most Frequently-Used Excipients in ESTRADIOL GEL?

# Of NDCs	Excipient
1	ALCOHOL
1	CARBOMER HOMOPOLYMER TYPE B
1	PROPYLENE GLYCOL
1	TROLAMINE

Estradiol Gel Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: August 15, 2026

Estradiol gel is a mature transdermal estrogen platform with continuing commercial opportunity in dose flexibility, skin tolerability, transfer control, packaging, and lower-cost generic supply. The core excipient systems are relatively simple: ethanol or another volatile solvent, a carbomer gel former, a neutralizing agent, water, and, in some products, propylene glycol. That simplicity lowers formulation barriers but increases the importance of device performance, bioequivalence, manufacturing consistency, and differentiated user handling.

What estradiol gel products are commercially available?

Estradiol gel products deliver 17β-estradiol through the skin for hormone therapy, primarily for treatment of moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause. In the United States, the principal branded products have included EstroGel and Divigel. Elestrin has also been marketed as a topical estradiol gel, although product availability and marketing status require confirmation through current FDA databases and commercial channels.

Product	Typical strength or dose	Delivery format	Core excipient strategy	Primary commercial distinction
EstroGel	0.06%; 0.75 mg estradiol per metered pump actuation	Metered-dose pump	Ethanol, carbomer, triethanolamine, purified water	Pump dosing and once-daily application
Divigel	0.1 mg/g, 0.25 mg, 0.5 mg, 0.75 mg, and 1.0 mg unit-dose presentations	Single-use sachet	Ethanol, carbomer, propylene glycol, trolamine, purified water	Multiple dose strengths and unit-dose packaging
Elestrin	Approximately 0.06% estradiol gel	Metered-dose pump	Alcohol-based carbomer gel system	Pump-based dosing and low application volume
Sandrena and Oestrogel	Varies by market	Sachet or pump	Alcohol, carbomer, neutralizer, water, with formulation-specific humectants	Non-U.S. market access and regional product positioning

Product composition and marketed status can change. FDA-approved labeling remains the controlling source for inactive ingredients, dose delivery, and application instructions [1-3].

Which excipients are used in estradiol gel?

The most common excipient architecture uses four functional components:

1. A volatile solvent, usually ethanol, to dissolve estradiol and promote rapid drying.
2. A polymeric thickener, usually carbomer, to create a spreadable gel.
3. A neutralizing agent, such as triethanolamine or trolamine, to adjust pH and develop viscosity.
4. Purified water as the principal aqueous vehicle.

Some formulations include propylene glycol as a cosolvent, humectant, and penetration-modifying excipient.

Excipient function and formulation risk

Excipient class	Typical examples	Primary function	Key development risk
Volatile solvent	Ethanol	Estradiol solubilization, rapid drying, skin permeation	Irritation, odor, flammability, excessive evaporation
Carbomer polymer	Carbomer 934 or 934P	Viscosity, suspension stability, residence on skin	Batch variability, neutralization sensitivity, poor spreadability
Neutralizer	Triethanolamine, trolamine	Carbomer activation and pH control	Viscosity drift, pH instability, skin tolerability
Humectant/cosolvent	Propylene glycol	Solubilization, water retention, skin feel	Irritation, altered permeation, extractables interaction
Aqueous vehicle	Purified water	Vehicle and hydration	Microbial control and physical stability
Packaging-contact materials	Pump, gasket, sachet laminate	Dose delivery and product protection	Adsorption, evaporation, dose variability, compatibility

The commercial opportunity is not based on discovering a new excipient. It is based on optimizing the interaction among excipients, dose volume, skin deposition, drying time, packaging, and patient handling.

How does excipient selection affect estradiol absorption?

Estradiol gel performance depends on more than the labeled estradiol concentration. The relevant variables include thermodynamic activity, solvent evaporation, polymer concentration, pH, viscosity, skin hydration, application area, and residual film formation.

Ethanol can improve initial estradiol solubilization and enhance penetration. As ethanol evaporates, the drug concentration in the residual film rises. That process can support transdermal delivery but can also produce local irritation and greater variability if drying conditions differ.

Carbomer controls residence time and spreadability. A gel that is too thin may run, transfer to clothing, or produce inconsistent application. A gel that is too viscous may reduce the area covered and increase dose variability. Neutralization is therefore a critical process parameter, not a simple cosmetic adjustment.

Propylene glycol can improve solubilization and skin hydration. Its inclusion may alter permeation and skin feel. A propylene-glycol-free formulation could have commercial value for patients with irritation or sensitivity, but it would require comparative pharmacokinetic and skin-tolerability work.

FDA labeling instructs users to apply the gel to specified areas, allow it to dry, wash hands, and avoid skin contact with others until the product has dried. These handling requirements create opportunities for improved formulation and packaging design [1-3].

What formulation patents protect estradiol gel products?

Estradiol gel protection can involve several patent categories:

Composition-of-matter and formulation patents

These may claim:

• Specific estradiol concentrations.
• Ethanol-water solvent ratios.
• Carbomer grades or concentration ranges.
• Neutralizer levels and pH ranges.
• Propylene glycol or alternative cosolvent systems.
• Defined viscosity or drying-time ranges.
• Preservative-free systems.
• Reduced-transfer or reduced-residue formulations.

Method-of-use patents

Claims may cover:

• Treatment of menopausal vasomotor symptoms.
• Treatment of vulvar and vaginal atrophy.
• Application to specific body sites.
• Dose titration or low-dose regimens.
• Reduction of systemic estrogen exposure.
• Use in patients with particular tolerability or adherence requirements.

Device and packaging patents

These may protect:

• Metered pump mechanisms.
• Dose-locking systems.
• Unit-dose sachets.
• Child-resistant packaging.
• Anti-leak valves.
• Low-residual-volume containers.
• Packaging that limits ethanol loss during shelf life.

For a generic applicant, formulation patents may be more important than broad estradiol composition claims because estradiol itself is an established active ingredient. Patent scope must be assessed claim by claim against the Orange Book, issued patent records, prosecution history, and product labeling. A product’s FDA approval does not establish that every patent claim covering the product is valid or enforceable.

What is the Orange Book status of estradiol gel?

FDA’s Orange Book identifies approved drug products, reference listed drugs, therapeutic equivalence codes, and certain patents and exclusivity information [4]. Estradiol gel is regulated as a small-molecule drug, not as a biologic. Its generic pathway is therefore an abbreviated new drug application, or ANDA, rather than a biosimilar application.

The relevant Orange Book analysis should examine:

• The reference listed drug for each strength and dosage form.
• Therapeutic equivalence codes.
• Listed formulation, method-of-use, and device patents.
• Patent-use codes.
• Whether a listed patent has expired, has been delisted, or remains subject to certification.
• Whether the reference product remains commercially marketed.

No single patent-expiration date applies to “estradiol gel.” EstroGel, Divigel, Elestrin, and non-U.S. products have separate regulatory histories and potentially separate patent estates. A patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and regulatory exclusivity. The current Orange Book is the appropriate source for operative U.S. listing information [4-5].

When does estradiol gel lose exclusivity?

Estradiol gel can lose commercial exclusivity through several separate events:

Exclusivity component	Commercial effect
Regulatory exclusivity	May delay certain ANDA approvals even if no enforceable patent remains
Formulation patent	Can delay or complicate generic launch if the claims cover the reference formulation
Method-of-use patent	May require a carve-out, skinny label, or litigation
Device patent	Can require a design-around pump or alternative package
Market withdrawal	May eliminate a reference product even if patents remain
Generic approval	Can reduce price and shift volume rapidly

For older estradiol gels, the primary risk is usually not biologic competition or new chemical-entity exclusivity. It is the combination of patent status, reference-product availability, ANDA substitutability, manufacturing cost, and payer pricing.

Which companies are challenging estradiol gel patents?

Generic competition is generally expected from manufacturers with topical semisolid and transdermal development capabilities. Potential participants include large generic companies, specialty-generic manufacturers, and contract development and manufacturing organizations with validated semisolid lines.

A Paragraph IV challenge would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor could then bring patent litigation under the Hatch-Waxman framework. FDA approval may be stayed for up to 30 months after timely receipt of notice, subject to statutory exceptions and litigation developments [6].

For estradiol gel, the most likely challenge targets are:

• Formulation claims directed to ethanol-carbomer systems.
• Dose-specific claims.
• Pump or sachet delivery claims.
• Application-site claims.
• Method-of-use claims that can be carved out of a generic label.

A generic applicant may avoid some method-of-use claims through a Section viii statement or labeling carve-out. That strategy is less useful when the protected use is inseparable from the approved indication.

What generic entry risks exist for estradiol gel?

Generic entry risk is material but technically manageable.

Bioequivalence risk

Topical gels can be difficult to demonstrate as equivalent because systemic exposure depends on application conditions and skin behavior. A sponsor may need comparative pharmacokinetic studies, in vitro characterization, or other FDA-required evidence. The relevant performance attributes can include:

• Estradiol and estrone exposure.
• Cmax and area under the curve.
• Dose uniformity.
• Spray or pump delivery performance.
• Viscosity and rheology.
• In vitro release.
• In vitro permeation.
• Residual drug after application.
• Drying time and transfer.

Manufacturing risk

Manufacturing barriers include:

• Uniform dispersion of low-dose estradiol.
• Control of carbomer hydration and neutralization.
• Ethanol evaporation during filling.
• Pump priming and re-priming.
• Filling accuracy at low dose volumes.
• Container-closure integrity.
• Long-term stability in commercial packaging.

Commercial launch risk

A generic can obtain approval but still face weak economics if:

• The reference product has limited volume.
• Multiple generic suppliers launch simultaneously.
• Payers prefer a low-cost alternative.
• The pump is expensive or difficult to source.
• The product has high patient counseling requirements.
• The sponsor cannot secure a reliable source of pharmaceutical-grade carbomer and compatible packaging.

What excipient opportunities exist for new estradiol gel products?

Lower-irritation gel systems

A low-ethanol or ethanol-free system could target patients with burning, dryness, or contact irritation. The technical challenge is maintaining estradiol solubilization and skin delivery without relying on high solvent activity.

Potential approaches include:

• Alternative cosolvents.
• Polymeric solubilization.
• Microemulsion or nanoemulsion systems.
• Reduced alcohol content.
• Buffered pH systems.
• Skin-conditioning excipients with low sensitization risk.

Reduced-transfer formulations

Estrogen transfer to partners or children is a recognized handling concern. A formulation that dries faster, leaves less residue, or forms a less transferable film could support premium positioning. Evidence would need to demonstrate transfer reduction under standardized contact conditions.

Improved metered dosing

Pump engineering can improve:

• Dose reproducibility.
• Priming behavior.
• One-handed operation.
• Dose locking.
• Remaining-dose visibility.
• Reduced container waste.

A device-led product can create defensible IP even when the gel composition is conventional.

Unit-dose presentations

Sachets can improve dose accuracy and portability. They can also reduce repeated air exposure and solvent loss. Their disadvantages are packaging waste, potential patient frustration, and the need to demonstrate complete emptying.

Lower-dose and titratable products

A broader dose ladder can support individualized therapy and reduce unnecessary estrogen exposure. Divigel’s multiple strengths illustrate the commercial value of dose flexibility [2]. A new entrant could compete through smaller dose increments, easier titration, or a package designed for dose escalation and de-escalation.

How does estradiol gel compare with patches, sprays, and creams?

Attribute	Estradiol gel	Transdermal patch	Estradiol spray	Vaginal cream
Dosing flexibility	High	Moderate	Moderate	Moderate
Skin contact duration	Short after drying	Multi-day	Short after drying	Local application
Visible residue	Possible	Adhesive and patch edge	Usually limited	Higher local residue
Application frequency	Usually daily	Often weekly or semiweekly	Daily	Varies
Device complexity	Low to moderate	Moderate	Moderate to high	Low
Transfer concern	Material	Lower after removal, but adhesive contact remains	Material	Primarily local
Generic development	Formulation and delivery challenge	Patch adhesion and release challenge	Device and dose challenge	Semisolid and local exposure challenge

Gel products occupy a middle position between patches and creams. They avoid adhesive problems and allow flexible dosing, but they require daily administration and careful counseling about drying and transfer.

What FDA regulatory issues affect estradiol gel commercialization?

Estradiol products carry class labeling requirements related to endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer risks associated with systemic estrogen therapy. Sponsors must maintain labeling consistent with FDA-approved indications and class warnings [1-3].

Regulatory priorities for a new or generic estradiol gel include:

• Demonstration of dose uniformity.
• Reproducible metered delivery.
• Stability of ethanol-containing formulations.
• Human factors for pumps and sachets.
• Container-closure compatibility.
• Skin irritation and sensitization.
• Transfer risk.
• Manufacturing control of low-dose content uniformity.
• Accurate patient instructions.

A novel excipient may increase regulatory complexity because the sponsor must establish its safety in the proposed route and exposure range. A conventional excipient system usually offers a more efficient development path, provided the sponsor can demonstrate equivalent performance.

What licensing deals and commercial partnerships are relevant?

The most practical licensing opportunities are likely to involve assets rather than individual excipients. Attractive transaction targets include:

• A validated estradiol gel formulation with human pharmacokinetic data.
• A differentiated pump or low-transfer package.
• Regional rights for an approved product.
• A generic-ready formulation with an established reference-product strategy.
• A contract manufacturing platform with controlled ethanol filling.
• A patent estate covering dose delivery or packaging rather than estradiol itself.

Deal value depends on the remaining patent term, regulatory status, product availability, manufacturing transferability, and payer positioning. A composition with only narrow excipient claims may have limited value if competitors can design around the claim using another carbomer grade, neutralizer, or package.

How strong is the patent estate for estradiol gel?

The likely strength of the estate is moderate for the active ingredient and potentially stronger for delivery implementation.

IP category	Expected durability	Design-around exposure
Estradiol active ingredient	Low for modern products	Not applicable
Basic ethanol-carbomer gel	Low to moderate	High
Specific excipient ratios	Moderate	Moderate to high
Dose-specific formulation	Moderate	Moderate
Pump and dose-control system	Moderate to strong	Moderate
Low-transfer performance claims	Variable	Depends on claim construction
Method-of-use claims	Variable	Often addressable through labeling
Manufacturing process	Moderate	High if process is not product-limiting

The strongest commercial protection may come from a layered strategy combining formulation claims, device claims, trade secrets for manufacturing, trademarks, and supply agreements. A single broad excipient patent is unlikely to provide durable protection against a technically capable generic sponsor.

Key Takeaways

• Estradiol gel is a mature small-molecule transdermal platform with generic and specialty-product opportunities.
• Core excipients are typically ethanol, carbomer, a neutralizer, water, and sometimes propylene glycol.
• The main formulation opportunities are lower irritation, reduced transfer, faster drying, improved dose accuracy, and better packaging.
• Generic entry risk is driven by bioequivalence, pump performance, formulation control, and Orange Book patent strategy.
• Estradiol gel has no biosimilar pathway because estradiol is a small molecule.
• Method-of-use, formulation, device, and packaging patents are more commercially relevant than active-ingredient patents.
• A differentiated pump or low-transfer formulation may have greater licensing value than a conventional gel composition.
• FDA labeling, patient handling, and estrogen class warnings materially affect commercialization.

FAQs

Is estradiol gel considered a biologic drug?

No. Estradiol is a small-molecule hormone. Generic versions are submitted through the ANDA pathway, not the biosimilar pathway.

Can propylene glycol be removed from an estradiol gel?

Yes, but removal can change solubility, viscosity, drying, skin permeation, and irritation. The replacement system would require formulation, stability, and comparative performance testing.

Does a lower ethanol concentration automatically reduce skin irritation?

No. Irritation depends on the complete formulation, including solvent activity, pH, polymer, neutralizer, application volume, and individual skin condition.

Are estradiol gel pumps patentable?

Yes. Patentable subject matter may include metering mechanisms, priming controls, dose locking, residual-dose reduction, container compatibility, and transfer-limiting delivery features.

Can a generic estradiol gel use a different excipient system?

Potentially. The generic must satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling. A different excipient system may increase development and regulatory requirements.

References

1. U.S. Food and Drug Administration. (n.d.). EstroGel (estradiol gel) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Divigel (estradiol gel) prescribing information.
3. U.S. Food and Drug Administration. (n.d.). Elestrin (estradiol gel) prescribing information.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension.
6. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certification and the 30-month stay under the Hatch-Waxman Act.